A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma

作者：Marcus R; Aultman R^*; Jost F

来源：British Journal of Cancer, 2010, 102(1): 19-22.

DOI：10.1038/sj.bjc.6605443

• follicular lymphoma
• cyclophosphamide, vincristine, and prednisone
• rituximab
• quality-adjusted survival
• health-related quality of life
• quality-adjusted time without disease symptoms or toxicities of treatment

BACKGROUND: To evaluate the impact of treatment on health states that affect patients' quality of life in advanced follicular lymphoma.
METHODS: A quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TwiST) analysis was performed on data from a phase III clinical trial (Marcus et al, 2008).
RESULTS: Cyclophosphamide, vincristine, and prednisone plus rituximab (R-CVP)-treated patients gained a mean of 15.17 months in TWiST, 8.33 months in Q-TwiST, and 11.30 months less in disease relapse, without increase in toxicity compared with cyclophosphamide, vincristine, and prednisone (CVP)-treated patients.
CONCLUSION: Rituximab plus CVP-treated patients reached a significant and clinically meaningful improvement within 12 months in quality-adjusted survival compared with CVP. British Journal of Cancer (2010) 102, 19-22. doi:10.1038/sj.bjc.6605443 www.bjcancer.

• 出版日期2010-1-5